Mepivacaine - Relmada Therapeutics
Alternative Names: MepiGel; REL-1021; TQ-1021Latest Information Update: 23 Feb 2023
At a glance
- Originator TheraQuest Biosciences
- Developer Relmada Therapeutics
- Class Local anaesthetics; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Diabetic neuropathies in USA (Topical)
- 23 Feb 2023 Discontinued - Preclinical for Neuropathic pain in USA (Topical)
- 23 Feb 2023 Discontinued - Preclinical for Postherpetic neuralgia in USA (Topical)